NASDAQ: DYAI Product Revenues Next Year
READ THE FULL DYAI RESEARCH REPORT
2Q:24 Operational & Financial Results
Dyadic International Inc. (NASDAQ
![](/images/icons/icon_biggrin.gif)
YAI) provided second quarter 2024 operational and financial results in a press release on August 13, 2024, filed its Form 10-Q with the SEC and held a conference call with investors. Since the last quarterly update, Dyadic announced a development and commercialization partnership with Iowa-based Proliant Health and Biologicals to sell animal-free recombinant albumin products produced by C1. It also signed another deal with a top 10 global dairy company for development of non-animal alpha-lactalbumin. Management attended several industry, trade and investor conferences in June updating stakeholders on recent progress.
https://finance.yahoo.com/news/dyai-product-r...00332.html
#nasdaq #stockstowatch #stockstobuy #DYAI @charles